How falling solar costs have renewed clean hydrogen hopes – MIT Technology Review

The world is increasingly banking on green hydrogen fuel to fill some of the critical missing pieces in the clean-energy puzzle.

US presidential candidate Joe Bidens climate plan calls for a research program to produce a clean form of the gas thats cheap enough to fuel power plants within a decade. Likewise, Japan, South Korea, Australia, New Zealand, and the European Union have all published hydrogen roadmaps that rely on it to accelerate greenhouse gas reductions in the power, transportation, or industrial sectors. Meanwhile, a growing number of companies around the world are building ever larger green hydrogen plants, or exploring its potential to produce steel, create carbon-neutral aviation fuel, or provide a backup power source for server farms.

The attraction is obvious: hydrogen, the most abundant element in the universe, could fuel our vehicles, power our electricity plants, and provide a way to store renewable energy without pumping out the carbon dioxide driving climate change or other pollutants (its only byproduct from cars and trucks is water). But while researchers have trumpeted the promise of a hydrogen economy for decades, its barely made a dent in fossil fuel demand, and nearly all of it is still produced through a carbon polluting process involving natural gas.

The grand vision of the hydrogen economy has been held back by the high costs of creating a clean version, the massive investments into vehicles, machines and pipes that could be required to put it to use, and progress in competing energy storage alternatives like batteries.

So whats driving the renewed interest?

For one thing, the economics are rapidly changing. We can produce hydrogen directly by simply splitting water, in a process known as electrolysis, but it's been prohibitively expensive in large part because it requires a lot of electricity. As the price of solar and wind power continues to rapidly decline, however, it will begin to look far more feasible.

At the same time, as more nations do the hard math on how to achieve their aggressive emissions targets in the coming decades, a green form of hydrogen increasingly seems crucial, says Joan Ogden, director of the sustainable transportation energy pathway program at the University of California, Davis. Its a flexible tool that could help to clean up an array of sectors where we still dont have affordable and ready solutions, like aviation, shipping, fertilizer production, and long-duration energy storage for the electricity grid.

For now, however, clean hydrogen is far too expensive in most situations. A recent paper found that relying on solar power to run the electrolyzers that split water can run six times higher than the natural gas process, known as steam methane reforming.

There are plenty of energy experts who maintain that the added costs and complexities of producing, storing and using a clean version means it will never really take off beyond marginal use cases.

But the good news is that electricity itself makes up a huge share of the costupwards of 60% or moreand, again, the costs of renewables are falling fast. Meanwhile, the costs of electrolyzers themselves are projected to decline steeply as manufacturers scale up production, and various research groups develop advanced versions of the technology.

A Nature Energy paper early last year found that if market trends continue, green hydrogen could be economically competitive on an industrial scale within a decade. Similarly, the International Energy Agency projects that the cost of clean hydrogen will fall 30% by 2030.

VOESTALPINE

Green hydrogen may already be nearly affordable in some places where periods of excess renewable generation drive down the costs of electricity to nearly zero. In a research note last month, Morgan Stanley analysts wrote that locating green hydrogen facilities next to major wind farms in the US Midwest and Texas could make the fuel cost competitive within two years.

A June study from the US National Renewable Energy Laboratory found it may be closer to the middle of the century before hydrogen is the most affordable technology for long duration storage on the grid. But as fluctuating renewables like solar and wind become the dominant source of electricity, utilities will need to store up enough energy to keep the grid reliably working not just for a few hours, but for days and even weeks during certain months when those resources flag.

Hydrogen shines in that scenario compared to other storage technologies, because adding capacity is relatively cheap, says Joshua Eichman, a senior research engineer at the lab and co-author of the study. To increase the length of time that batteries can reliably provide electricity, you need to stack up more and more of them, multiplying the cost of every pricey component within them. With hydrogen, you just need to build a bigger tank, or use a deeper underground cavern, he says.

For hydrogen to fully replace carbon-emitting fuels, wed need to overhaul our infrastructure to distribute, store, and use it. Wed have to produce vehicles and ships with fuel cells that convert hydrogen into electricity, as well as fueling stations along ports and roads. And wed need to stack up fuel cells or build or retrofit power plants to use the fuel to power the grid directly.

All of which will take a lot of time and money.

But theres another scenario that sidesteps, or delays, much of this infrastructure overhaul. Once you have hydrogen, its relatively simple to combine it with carbon monoxide to produce synthetic versions of the fuels that already power our cars, trucks, ships, and planes. The industrial process to do so is a century old and has been used at various times by petroleum-strapped nations to make fuels from coal or natural gas.

CARBON ENGINEERING

Carbon Engineering, based in Squamish, British Columbia, is developing facilities that capture carbon dioxide from the air. The company plans to combine it with carbon-free hydrogen to make synthetic fuels. The idea is that the fuel will be carbon neutral, emitting no more carbon dioxide than was removed or produced in the process.

In a presentation at a Codex conference late last year, Carbon Engineering founder and Harvard professor David Keith said that falling solar prices should enable them to bring air-to-fuels to market for about $1 a liter (around $4 per gallon) in the mid-2020sand that the price will continue to fall from there.

The big news here is that this could be done with commodity hardware starting soon, he said. You could get to something like a million barrels a day of air-to-fuels synthetic hydrocarbon capacity, I think, soon after 2030, and after that theres no obvious scaling limit.

In effect, the process provides a way to convert fleeting, fluctuating solar power into permanently storable fuels that can fill the tanks of any of our machines. This is about an energy pathway to deal with the intermittency problem and deal with it in a way that allows you to power high-energy density needs around the world; allows you to fly airplanes across the North Atlantic, Keith said.

More here:

How falling solar costs have renewed clean hydrogen hopes - MIT Technology Review

Local company uses new timed technology to fight spread of COVID-19 – WXYZ

(WXYZ) As the COVID-19 pandemic continues, businesses are adjusting through new technology and trying to prevent the spread.

Washing your hands at Griffin Claw in Birmingham these days is a little more strategic. The microbrewery installed new faucets in the restrooms that make sure each wash is thorough killing germs.

Christopher Lasher, Griffin Claw's marketing director explained, "They're touch free sensors. They time the amount of time that the water comes out and the soap dispenses automatically, after five seconds of water and then there's a 20 second time period for lathering with just the soap."

And then comes the rinse which lasts for as long as your hands are underneath the faucet.

As Lasher explained, this isn't the first time Griffin Claw's made news for helping people keep their hands clean. In March, the business made use of its unique machinery and converted its operations to produce hand sanitizer during a national shortage.

"We gave free sanitizer with every carry out order. We were able to provide sanitizer to the state of Michigan and everyone else. So that was a source of keeping us going," Lasher said.

Right before reopening dine-in during the pandemic, Lasher says the business wanted the taproom experience to be a breath of fresh air.So the brewery installed three air purifiers that he points out will really come in handy in the colder months.

"In the summer, with the open air we can have large doors open. It's nice to get fresh air throughout the area but as far as our guests being safe and comfortable as well as our employees who have to be here all day... we want them to feel as safe as possible and actually be as safe as possible," he said.

"So it was just worth the investment to bring in these types of technologies," Lasher added.

Read the rest here:

Local company uses new timed technology to fight spread of COVID-19 - WXYZ

Technology reshaping the field of sports fandom – Business in Vancouver

With live game attendance yet to resume, tech firms are helping reshape the fan experience through online platforms|Rob Kruyt

Turn the TV volume high enough and perhaps even the faint echoes of the puck dropping at Rogers Place in Edmonton will be heard by Vancouver fans left with no option but to watch from home.

With the Canucks battling against the Minnesota Wild in the National Hockey League (NHL) playoffs qualifying round in early August, the fan presence in the arena was as lacking as Vancouvers offence in Game 1.

But with COVID-19 restrictions leaving the stands empty, expect the role of social media to reshape fandom this season.

Weve always looked at sports on Twitter [Inc. (NYSE:TWTR)] as an opportunity for sports fans to engage as if it were a virtual sports bar, said Conor Clarance, head of sports at Twitter Canada. Its where you can go to find that niche conversation. You can find your Canucks fans, you can find your BC Lions or your Whitecaps fans outside of the stadium.

What weve seen now is that conversation has only grown as theres this potential for no fans in stadiums and how long is that going to last, etc., etc. So theres a ton of excitement around being a sports fan and having that ability to have that conversation and cheer on your team on Twitter. And that seems to only be growing as sports kind of comes back now in their new forms.

Hockey conversation on Twitter grew 114% upon the resumption of the NHL season during the first weekend of August compared with the last weekend before the pause to the season in March, according to data provided to BIV.

Clarance said it also helped that six out of seven Canadian NHL teams played over that August weekend.

Clarance, who works with leagues, broadcasters and publishers to help them connect with fans over Twitter, said the long absence of pro sports leagues in North American sports leagues has created pent-up demand for their return.

Major League Soccer (MLS) was first out of the gate last month, followed by Major League Baseball (MLB) the latter of which has seen COVID-19 outbreaks ravage teams as they travel rather than play in hubs like NHL and National Basketball Association (NBA) teams.

Twitter Canada observed a 58% year-over-year spike in baseball conversations the weekend games resumed in late July.

When you think about a Canadian audience that is predominantly fans of the lone Canadian baseball team [Toronto Blue Jays], thats a pretty sizable jump, he said.

What youre going to see is likely the largest month of sports conversation ever this September when you look at this sort of perfect storm we have of six major leagues NFL, NBA, MLS, NHL, PGA Tour [and MLB] all happening at the same time within the month.

Clarance anticipates the roar of the stadium crowds will ultimately transition to conversations over Twitter for now.

The communal aspects of sports are missing when you cant attend games, Andrew Selepak, a professor specializing in social media at the University of Florida, said in an email to BIV.

This is where the social media marketing for teams is essential, Selepak said. Social media accounts for professional sports teams need to provide not only the content that fans want, but the communal experience that fans crave.

He said it will be up to teams to encourage their fans to engage in second-screen experiences, with their TVs tuned to the game while they have their smartphones in their hand as they tweet, post to Facebook (Nasdaq:FB) or follow along with specific hashtags.

Teams could set up live feeds from the bench or get exclusive in-game interviews, hold online contests, post polls, request user generated content and so much more, he said. Social media is already about engagement, but with in-person engagement limited during the pandemic, this is when a teams social media has the opportunity to expand their role and get fans interested.

Meanwhile, made-in-B.C. technology has already been capitalizing on this transition.

Victoria-based SendtoNews Video Inc. is best known for its video distribution platform for sports highlights that are showcased within online stories for publications such as the Los Angeles Times or the Chicago Tribune.

Last month SendtoNews touted new Comscore Inc. (Nasdaq:SCOR) rankings that show the company attracted more than 47 million unique viewers responsible for more than one billion video views in May.

Three years ago thats what we did in a year and now we do it in a month, and we see that trend continuing, CEO Matthew Watson told BIV in July.

See the rest here:

Technology reshaping the field of sports fandom - Business in Vancouver

cred.ai Emerges From Stealth Mode To Debut Technology-Powered Metal Card With Unrivaled, Premium Features For Millennials and Gen Zers That Guarantees…

PHILADELPHIA, Aug. 6, 2020 /PRNewswire/ -- Today, cred.ai, a Philadelphia-based fintech company, introduced a new kind of consumer spending product that leverages proprietary technology to give users first-of-their-kind controls, convenience, and automatic credit score optimization. While customers never pay fees or interest thanks to the cred.ai Guaranty, they also receive a premium brand experience delivered through a solid metal Visa card, and mobile app anchored by the content of cred.ai's progressive media division crednews. cred.ai has operated in stealth for the past 3 years, and closed a successful Series A led by prominent investors including David Adelman, CEO of Campus Apartments; former CEO of AOL and president of Google America and current founder of DTX, Tim Armstrong; and executive chairman of Fanatics and partner with the 76ers, Michael Rubin, as well as a group of individual celebrity investors.

"Banking is so regulated, so antiquated, so daunting, it's understandable why consumer card products have barely changed over the past decade," said Ry Brown, cred.ai CEO and co-founder. "Thankfully, we're a crew of hackers, artists, and scientists, with just a couple recovering bankers in the mix." While cred.ai's in-house talent ranges from astrophysicists to 3D Animators, several of its "recovering bankers'' were the founders of ING Direct, the beloved $90 Billion "good guy" bank. "Our outsider perspective has been one of our greatest assets. We're not imprinted with traditional concepts of what's possible or expected, so we get to believe we can tackle any idea we dream up, as long as we have enough coffee."

The core cred.ai consumer product functions through the combination of an FDIC insured deposit account, the Unicorn Card Visa credit card, and the cred.ai mobile app. cred.ai real-time automation ensures the consumer experience is essentially like a superpowered debit card. User's never worry about fees, interest, or payments, while taking advantage of cred.ai's unique set of technology features and controls. WSFS Bank, the largest locally headquartered bank in the Philadelphia region, provides the FDIC insured deposit account and issues the Unicorn Card Visa credit card.

Exclusive features are introduced continuously, with the current roster including: self-destructing virtual "Stealth Cards" designed for risky transactions; "Flux Capacitor" allowing users to see future transactions and automatically spend or budget accordingly; "Check Please" eliminating the embarrassment of card declines at important rendezvous; Credit Optimizer (see details below); the "Friend & Foe" systems allowing users to directly manage the trust and permissions of individual merchants in real-time; and "High Security Mode" generating secure finite authorization windows. In addition to these exclusive tech features, all users receive a full face true metal card, 24/7 phone support answered by a human and not a robot, instant deposits, mobile check capture, payroll and other direct deposits two days early, and an onboarding process that allows users to start spending within minutes of applying.

Millennials and Gen Zers have a natural aversion to credit cards, due to a fundamental distrust of debt and the banking system overall. "The Apple Card is a stunning product, but if you're opposed to credit cards in general, it's just not a product for you," said Dylan Brown, cred.ai president and co-founder. For these credit card averse consumers, cred.ai's automatic credit optimization is their best way to build credit without fear. Other products that claim to build credit focus merely on reporting on-time payments, which minimally affects credit profiles, usually via commonly undesirable "secured" cards. Far more precisely, cred.ai's Credit Optimizer is able to affect credit utilization, which is known to be one of the most significant factors contributing to credit profiles. "The other products don't use an optimization algorithm or anything adaptive. Worse, they are attached to subprime products that don't provide much in terms of experience," said Dylan. The cred.ai CreditOptimizer was built to be card agnostic and is capable of managing and optimizing most third-party major credit cards, beyond just the Unicorn Card. cred.ai plans to publicly open third-party card management integration in Q1 of 2021.

"Millennials swipe a lot on social media, but this is a major swipe at disrupting banking. cred.ai is this generation's version of an Amex Black Card," said cred.ai investor Tim Armstrong, Founder of the DTX Company and former CEO of AOL, Oath, and President of Google America. " Millennials don't care about meaningless points and lounge access hiding amongst hundreds in fees, they care about becoming financially stronger, technology and features on the cutting edge, and companies with values they align with."

While cred.ai has plans to offer ongoing cashback and rewards opportunities, it is not designed for points aficionados. "Our users know that traditional cashback is a karma trap," said Dylan. "For an average user, the actual cash back earned winds up being very small, and gets outweighed by fees and interest. But the real issue is that those flashy rewards are supported and subsidized via the suffering of that bank's lower income customers. It's wealth redistribution in the wrong direction."

"We realized early on, that if you want to build something that changes people's lives, you need to actually build. The reason every bank and fintech card offers such sparse, identical features is because they are basically white-labeling the same stock platforms with a different logo," said Lauren Dussault, cred.ai chief banking officer. " Over two and a half years were spent building the banking technology and compliance foundation that makes the complex features of cred.ai possible. "We don't view infrastructure as merely a means to an end," said cred.ai Co-Founder and COO Todd Sandler. "We see it as another opportunity to build a phenomenal product, where we ourselves are the first customer. Operating like that allows us to iterate our consumer product faster, and derive value directly from the technology itself." The platform itself includes full compliance management, and was built modularly so that it can also be licensed to provide "bank in a box" operations for small banks and brands. "When we built ING Direct, our goal was to leverage technology to operate with 10% of the resources a traditional bank would use," said Jim Kelly, chairman and co-founder of cred.ai, and founding COO of ING Direct. "With what we've built at cred.ai, I think we get that down to 1%." Multiple licensing deals are currently in the works, with announcements expected in Q4 of 2020.

"I think cred.ai could one day be viewed as the Tesla of banking," said cred.ai co-founder and lead investor David Adelman. "We approached an antiquated and rigid sector as if limitations didn't exist, with the conviction that we could use hard work and creativity to rebuild it into something fundamentally better." That conviction also extends to cred.ai's views on social and world affairs, best displayed through crednews, the media division that produces the original documentaries and journalistic content that anchor the mobile app experience. This progressive spirit has attracted celebrity investors like John Legend and superstar athletes like Andre Iguodala. "It's a rare product they can proudly endorse for being altruistic, and then benefit from being users of the product themselves," said David.

"cred.ai will serve different purposes to different users," said Dylan. "For some it will be their solution to building credit without fear. Early adopters will see it as their gateway to the most advanced features. Stealth Card alone will be the reason many people sign up. Some will be drawn to our progressive beliefs, and others might just want a cool, free metal card. Regardless of the motivation, the fact that the product can be top of wallet for both a college student or a wealthy NBA superstar, says a lot about our mission to build a premium product for all people."

Today consumers can apply to join cred.ai's limited private beta, during which participants will be given the opportunity to share their view on how advanced financial technology would impact their life goals. Of the participants that share their stories, some will be selected to receive $10,000 from cred.ai to help them reach the goals they describe. See http://www.cred.ai/beta for official rules.

"Don't call us a bank. I don't even like being pigeonholed as fintech," said Ry. "Right now we're building products that help empower people financially, but next we could throw in education, health care, insurance, who knows. Whatever it is, we'll dream it, build it, and then give it away for free."

About cred.aiVisit http://www.cred.ai to apply for beta access. cred.ai is based in Philadelphia, PA and has been operating in stealth for over three years building free financial technology designed to empower consumers and elevate their financial services experience. The cred.ai deposit account is provided by Wilmington Savings Fund Society, FSB ("WSFS Bank"), Member FDIC. The Unicorn Card credit card is issued by WSFS Bank pursuant to a license from Visa U.S.A. Inc. and may be used everywhere Visa credit cards are accepted. Learn more at https://www.cred.ai

About WSFS Financial Corporation WSFS Financial Corporation is a multi-billion-dollar financial services company. Its primary subsidiary, WSFS Bank, is the oldest and largest locally managed bank and trust company headquartered in Delaware and the greater Philadelphia region. As of June 30, 2020, WSFS Financial Corporation had $13.6 billion in assets on its balance sheet and $20.8 billion in assets under management and administration. WSFS Financial Corporation operates from 115 offices, 90 of which are banking offices, located in Pennsylvania (54), Delaware (43), New Jersey (16), Virginia (1) and Nevada (1) and provides comprehensive financial services including commercial banking, retail banking, cash management and trust and wealth management. Other subsidiaries or divisions include Arrow Land Transfer, Cash Connect, Cypress Capital Management, LLC, Christiana Trust Company of Delaware, NewLane Finance, Powdermill Financial Solutions, West Capital Management, WSFS Institutional Services, WSFS Mortgage, and WSFS Wealth Investments. Serving the greater Delaware Valley since 1832, WSFS Bank is one of the ten oldest banks in the United States continuously operating under the same name. For more information, please visit http://www.wsfsbank.com.

Press contact:Matthew Mirandi[emailprotected]

SOURCE cred.ai

cred.ai – we make supercards

See more here:

cred.ai Emerges From Stealth Mode To Debut Technology-Powered Metal Card With Unrivaled, Premium Features For Millennials and Gen Zers That Guarantees...

Stafford duo helping police fight organised crime with their new AI technology – expressandstar.com

Stafford-based Semantics 21 (S21) has developed artificial intelligence technology purely for digital forensics which is being used by police across the globe.

Its being deployed in cases of child exploitation, counter terrorism, human trafficking and other serious organised crime.

The technology is able to sift through evidence with the help of automated searches based on visual similarity or recognition of faces, age, emotion, nudity and a variety of object types.

It can work through millions of images in minutes to jigsaw together the smallest details to identify victims and perpetrators.

As well as helping rescue more victims, the AI is also helping to safeguard the mental health of many investigators who would normally have to examine horrific images to catch perpetrators and stop criminal gangs.

The duo behind the firm, which has worked with forces in the UK including Staffordshire Police as well as those in Canada and the US are Dr Liam Owens and Prof Claude Chibelushi, who are both from Stafford.

Although they cant reveal specific details of cases or forces, for legal reasons, the pair know their AI is responsible for helping one force solve more cases and find more victims in 12 months than the previous three years and for assisting another in reducing a case backlog of several months down to zero.

It was while studying for a Ph.D. in digital forensics at Staffordshire University, under Claude, that Liam spent time working with investigators, where he quickly realised how a specifically designed digital forensics AI system could be a major boost to the polices crime-fighting armoury.

Liam, 32, who usually spends his time travelling the globe to support and train forces in its unique AI, said: During my university studies, and while working with some incredible investigators back in 2009, I saw the overwhelming backlog they were facing, and I was shocked by the complete lack of clever tech available to assist investigators, including a lack of AI for victim ID.

Like in many industries it sometimes takes an outsider with insider knowledge to patch the issue and that is what we developed this tech specifically for.

Claude exposed me to leading edge research available now, and the future of

the AI marketplace. But I saw first-hand that forces didnt have the opportunity to invest in tools harnessing the best computing AI had to offer to assist them there and then. We wanted to bring forces into the 21st century by bridging the semantic gap between humans and computer, hence the name Semantics 21.

So, we developed our own unique AI and innovative products specifically designed for digital forensics.

Our long term goal is for people to see us as global leader in digital forensics and AI across the world, we are pioneering the research and putting it out when tried, tested and proven ready to go.

Father-of-three Claude left lecturing at the university to run the company, which received a Queens Award for Enterprise, in the Innovation category, last year, full-time with Liam.

Excerpt from:

Stafford duo helping police fight organised crime with their new AI technology - expressandstar.com

Surface Testing Technology Available Throughout the Nation Through Bactronix Franchise Network – PRNewswire

MOON TOWNSHIP, Pa., Aug. 7, 2020 /PRNewswire/ --Surface testing is now attainable for organizations and households throughout the nation thanks to Bactronix and its extensive franchise network.

Bactronix, a science based microbial control company, is the first to invest in advanced technology for testing coronavirus / SARS-CoV-2 on environmental surfaces. "Since the pandemic entered the United States in January of 2020 we have been working with manufacturers of laboratory equipment to develop a testing system for surface testing of coronavirus," stated Jos Kleynjans, President and CEO of Bactronix and one of the founders of the company. "Introducing this testing technology is exciting news for our franchisees, our customers, and everyone who will utilize our services in the future."

The company has been on the front lines of the pandemic since the beginning due to its environmentally responsible, sanitizing products and hospital-grade disinfection services, including the proprietary Bactronizing process. Bactronix also offers specialized air duct and dryer vent cleaning along with mold remediation, vapor barriers, and insecticide services.

Now, being the first company in the United States to have the ability to test for SARS-CoV-2 contamination on surfaces, Bactronix has set a new standard as a leading Microbial Control Company. "Not only do we have the ability to test the surfaces, we have a complete in-house laboratory set-up to provide quick turnaround time for test results," stated Kleynjans. According to Kleynjans, testing is applicable within a variety of settings. All tests are done by Certified Bionomic Specialists and can be done on both hard and soft surfaces in homes, schools, offices, restaurants, care facilities, medical facilities, vehicles, planes, and other settings.

Bactronix invites those interested in learning more about their testing services to their website atwww.Bactronix.com. For those wanting to learn how to become a part of the Bactronix franchise network, visithttps://bactronix.com/index.php/franchising-opportunities.

ABOUT BACTRONIX

Bactronix is an award-winning, science-based microbial control company that uses proprietary products and advanced equipment for a wide range of disinfection and mold removal services. Their certified personnel are highly trained in administering effective, eco-responsible disinfection treatments for commercial and residential facilities. For more information on their franchise opportunity, visithttps://bactronix.com/index.php/franchising-opportunities.

Media contact:Jos KleynjansBactronix412-375-7886http://bactronix.com

SOURCE Bactronix

Home

More:

Surface Testing Technology Available Throughout the Nation Through Bactronix Franchise Network - PRNewswire

Nokia will not be involved in the geopolitical technology war – Gizchina.com

Since last year, there have been a salient but serious war in the technology industry. This war is basically between the U.S. g0vernment and Chinese companies. The American government is dragging its allies into the war. Most recently, India also started a battle with Chinese companies. However, India seem to have its own agenda which is different from that of the Americans. As a competitor, other companies are indirectly linked with growing tech war. According to Nokias new CEO, Pekka Lundmark, competitors have to be careful. For the Finnish company, it does not want to be part of the trade and political conflicts. The new CEO of Nokia said that the company will eliminate geopolitical entanglement and maintain a neutral position.

Presently, the U.S. is using its prowess to prevent Chinese company, Huawei, from entering the global 5G mobile network market. This opens up more opportunities for Nokia in the 5G network equipment market. However, Lundmark, who took over the power of Nokia on August 1, is seeking his own foothold.

I think it would be a major mistake if a single company starts to promote their political agenda Lundmark said in an interview with the media on Friday. It is very important for companies to be straightforward and do what they should do. We have no political agenda, we are a pure enterprise.

The Donald Trump administration has been pressing its allies to ban Huaweis equipment citing security risk. Although there is no significant evidence and Huawei has to cope with bans in multiple regions.

Huawei is not the only Chinese technology company that is suffering from the ban by the U.S. A few days ago, Trump signed an order to ban TikTok, a foreign version of the Chinese app Douyin. This app is very popular among Americans especially its young users with over 90 million active monthly users. The ban also hit other Chinese apps like WeChat.

Nokia has since acknowledged that the ban on Huawei is bring some business to the company. In fact, the U.S. and U.K. will provide someassistance to Nokia and its Swedish rival, Ericsson. This is to ensure the competitiveness of its 5G equipment supply.

Nokia lags behind its competitors in the 5G network equipment market, which is why Lundmark was hired as the new head of Nokia. Just five days after taking up the position of Nokias new CEO, Lundmark said he is busy talking with customers and has begun to plan a way forward for the company. Nokias CEO added

It is extremely important to maintain good relations with almost all regions and governments in the worldWe communicate with governments in different regions of the world, and it is just as usual for us. What we have to do now is to preview the current plan and then formulate a new plan on how to develop it. I already have some theories and ideas in my mind, but its too early to talk about these theories. Im only five days old in the office and cant make deep statements. Nevertheless, my goal is firm, with regard to what should we do next in the market. We will say something more specific before the end of the year.

Read the original:

Nokia will not be involved in the geopolitical technology war - Gizchina.com

NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403 -…

SEATTLE--(BUSINESS WIRE)--Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research (SBIR) Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial.

The clinical trial, conducted at University of California, San Francisco with Dr. Rahul Aggarwal as Principal Investigator, is a 30-40 patient dose escalation/expansion trial in men with advanced castration-resistant prostate cancer. The trial is designed to show safety and efficacy of CTT1403 and is halfway through the initial dose escalation phase. To date there have been no safety issues with the drug and the pharmacokinetic data support the longer circulation time of CTT1403 in the blood stream as compared to other PSMA agents currently in clinical trials. "These PSMA-targeted agents are already transforming how prostate cancer is diagnosed and treated and we are very pleased that the NIH continues to support the development of these exciting new agents. CTT1403, with its longer circulating time and better tumor targeting characteristics, offers distinct advantages in this treatment arena providing the patient with cost and treatment benefits, commented Dr. Beatrice Langton-Webster, CTTs CEO and Principal Investigator on the grant. The unique chemical structure for CTT1403 was conceived of by Dr. Cliff Berkman, Professor at Washington State University (WSU).

CTT1403 targets Prostate Specific Membrane Antigen (PSMA) which is over-expressed on prostate cancer. Two features make CTT1403 unlike other PSMA-targeted drugs currently in development: 1) Due to a unique core scaffold, CTTs molecules bind irreversibly to PSMA and this distinctive mode of binding enables rapid uptake of the drug within the tumor; and 2) CTT1403 is engineered to increase the circulation time of the drug in the body which further substantially increases the dose of drug that accumulates at the tumor sites. CTT1403 is labeled with the radionuclide Lutetium-177 and once delivered to the tumor, the radionuclide acts to destroy the tumor cells.

CTT completed two clinical trials at UCSF with CTT1057, the companion PET diagnostic imaging agent to CTT1403, with excellent safety and imaging results for both prostate cancer and renal cell carcinoma. CTT1057 is undergoing further development for prostate cancer by CTTs licensing partner AAA/Novartis. CTT1057 and CTT1403 serve as a theranostic pair to both diagnose and treat solid tumors that express PSMA, and are being used together in the current clinical trial. More information on the trial can be found at clinicaltrials.gov.

Read the original here:

NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403 -...

The Lefts Brilliantly Deceptive Documentary Alt-Right …

One of the biggest goals of the left in recent years is to portray those on the right as racists. It saves them the effort of having to refute the rights arguments substantively. If they are successful, they can discredit all of the rights viewpoints since theyre views held by racists. There are few white supremacists left, but the media and left love to feature them as if theyre a huge threat from the right.

One way theyve set about accomplishing thisis through use of the term alt-right. They use it to lump white supremacists in with some regular conservatives who are dissatisfied with the mainstream Republican establishment. Its a brilliant tactic, since the two are not similar, but it makes people start to think they must be.

The reality is many white supremacists are on the left. The National Socialist Party, which callsitself the largest and most active National Socialist party in America, has plentyof views on the left.

The right denounces white supremacists and kicks them out of their events. There is no overlapping. And this is nothing new. Back in the 1960s, William F. Buckley Jr., editor of National Review, ensured that racists were not allowed in the conservative movement. As one of his biographers wrote, Buckley stood guard over the movement he founded and in what he called his greatest achievement kept it free where he could of extremists, bigots, kooks, anti-Semites and racists. In 1993, Buckley fired Joseph Sobran over a series of columns he considered antisemitic. Buckley and National Reviewdefined the essence of conservatism for multiple decades, so this was nothing to be dismissed.

Adam Bhala Lough recently wrote and directed a documentary currently popular on Netflix entitled Alt-Right: Age of Rage. But the only people on the right it features are white supremacists (some may call themselves white nationalists or other variations). There are no white supremacists on the left. The ones featured are shown saying vile things followed by conservative viewpoints; its very cleverly done, as if white supremacist and right wing are interchangeable. One headline states, Right-wing e-zine calls for black genocide. Racist images are posted in a row followed by Breitbart logos.

The left is represented by Daryle Lamont Jenkins, a charismatic black man who is a member of Antifa. Now that already raises red flags, because Antifa is almost completely white. So theyre trying to portray the violent hate group Antifa as a likable black man. They show him criticizing racism repeatedly and posing next to paintings of civil rights leaders. He brings up his military background, saying he took an oath to defend against foreign and domestic enemies. But both the right and the left find this admirable.

Antifas violent tactics are mostly ignored, except when one punches one of the worst white supremacists in the face, Richard Spencer. He is the main white supremacist featured and interviewed, a truly vile human being who is probably the most well-known since he craves attention. He says horrible things about Jenkins, like claiming he weighs at least 400 pounds and is gross looking. When he runs into him, he tells him he thought he would be dead by now because of obesity. To tie him to conservatives, Spencer is pictured standing in front of the Jefferson Memorial, then giving a speech where he yells Hail Trump! He denounces multiculturalism.

What the documentary wont tell you is that Spencer was kicked outof CPAC, the leading annual national conservative conference, in 2017 when he tried to show up. CPAC spokesman Ian Walters said Spencer wasnt a conservative, "He's anti-free markets, anti-Constitution, anti-pluralism."

Jenkins helpfully lumps Spencer in with the right by referring to Spencer as a right-wing propagandist, which is the same phrase someone on the left might use to label anyone on the right. Jenkins blames President Trump for giving them their juice. He uses Trump supporters interchangeably with white supremacists. The late Andrew Breitbart, a leading figure in the conservative movement during this century, is shown yelling at Jenkins to get out of his face, but tellingly the documentary doesnt reveal why. Breitbart was Jewish and hates racists. Jenkins says he goes after the National Socialist movement but there is no admission that the group is more on the left.

Another white supremacist the documentary prominently features and interviews is Jared Taylor, the founder of the racist site American Renaissance. Superficially, he looks like a traditional statesmanlike conservative and uses a tone of voice that sounds like it could be any thoughtful person on the right except vile things come out. He decries the people who criticize him in patriotic terms, saying Were the land of the free and the home of the brave. It is no coincidence he was chosen for this documentary. He puts on an annual conference of white supremacists every year, and complains that because of the efforts against him, they had only 300 show up instead of 400-450. Yep, thats how many in the entire U.S. would show up. Protesters show up outside his conferences. Tellingly, they are practically all white most black people realize his group is just a handful of losers who no one pays attention to except the media.

Mark Potok of the Southern Poverty Law Center chimes in periodically to reinforce the connection. He says that Dylann Roof, who shot and murdered people in a black church, was influenced by the radical right, a term commonly used for regular conservatives. He says there has been a rise in racist groups which might seem believable if youre now lumping in regular conservatives. Nowhere is it revealed that the SPLC is itself a hate group, labeling regular Christian organizations as hate groups. Its great to hear Potok denounce white supremacy but thats something we all agree on except a handful of white supremacists. Someone knowledgeable on the right could easily have sat in his place and said the same things.

The documentary covers the deadly Charlottesville riots of 2017. That event played right into their hand, because its organizer, Jason Kessler, a known white supremacist, named the rally Unite the Right as if he was including regular people on the right too. Its not very likely there were regular people on the right there, because one of the speakers saidthe rally was meant to unify various white nationalist factions against unidentified enemies. But the title even fooled President Trump, who denounced the violence but said there were "very fine people on both sides. Taylor helpfully stated that Trump appeals to those who are racially conscious. Even if true, as Ive explainedpreviously, this is no reflection on Trump.

People on the left are shown saying in interviews that they denounce violence by their side, while the white supremacists are shown saying its necessary. Jenkins says violence should only be engaged in as a form of defense, but we all know thats not representative of Antifa.

The problem is conservatives dont understand whats happening to us. They blindly accept the clever lumping in of white supremacists with regular conservatism and accept the phrase alt-right. I dont know anyone personally who refers to themself as the alt-right. Why dont conservatives create a documentary about the leftists in the National Socialist Party, the white supremacists who supportedHillary Clinton andBarack Obama as well as the antisemites in the Democratic Party vs. the conservatives who fight that racism? Perhaps feature the group Patriot Prayer, which is run by minorities and finds itself frequently the victim of Antifa, and gay Asian reporter Andy Ngo who covers these protests and was savagely beaten by Antifa. Maybe call it Alt-left and contact me to help fundraise.

Original post:

The Lefts Brilliantly Deceptive Documentary Alt-Right ...

Researchers Explain the Origins of Stony-Iron Meteorites – HeritageDaily

Pallasites are stony-iron meteorites, and are known for their unusual, visually attractive structures. However, to date, their origins have been hotly disputed.

Researchers at the Bavarian Research Institute of Experimental Geochemistry & Geophysics (BGI) of the University of Bayreuth have now succeeded in simulating the formation of all known types of pallasites by means of high-pressure experiments, and in placing them in the history of the solar system. They have been working closely with scientists from the Technical University of Munich and the Royal Holloway University of London. The new findings are presented in the journal Earth and Planetary Science Letters.

As the researchers have now discovered, pallasites arose from asteroid collisions that occurred approximately 4.5 billion years ago. In these collisions, iron from the smaller asteroid mixed with the olivine-rich material in the mantle of the larger asteroid. Billions of years later, quantities of this material mixture were blasted out of the surface of the asteroid by the force of another impact, and catapulted into space. Some of them finally hit the Earth. This genesis explains the unusual structures found in pallasites: They contain greenish brown olivine crystals surrounded by nickel and iron metal.

In research, the spatial arrangement of different materials in a rock and the resulting structures make up what is called texture. The pallasites that have been found and studied on Earth so far show a very large variety of textures. With our research work, we were able for the first time to reproduce in the laboratory all of the textures observed in pallasites.

This shows in an exemplary way how these meteorites can provide us revealing and unexpected insights into the early history of our solar system. To this end, we wish to continue our structural and chemical investigations of pallasite meteorites at BGI especially in the geochemical laboratories soon to be established here, says Prof. Dr. Audrey Bouvier, Professor of Experimental Planetology at the University of Bayreuth.

The new findings are the result of experiments on two extremely powerful devices: the MAVO high-pressure press at the Bavarian Research Institute of Experimental Geochemistry & Geophysics, and the identical SAPHiR high-pressure press. This is currently being set up with the assistance of Prof. Dr. Hans Keppler from BGI at Forschungs-Neutronenquelle Heinz Maier-Leibnitz (Research Neutron Source Heinz Maier-Leibnitz) at the Technical University of Munich.

With these instruments we can simulate very realistically the processes that led to the formation of meteorites, asteroids, or the planets. In order to be able to explain the formation of pallasites by asteroid collisions, we imitated the pressure and temperature conditions prevailing during these processes. Thus, we subjected samples containing iron and olivine to a pressure of one gigapascal (GPa) at 1,300 degrees Celsius. We then compared the changes in shape and internal stresses that we observed in the experimental samples with the textures found in the pallasite meteorites, explains Danielle Silva Souza, a Masters student from Bayreuth. After her bachelors degree in geosciences at the Federal University of Ouro Preto in Brazil, she came to Upper Franconia to work on experimental geoscience projects, which included the geochemical and experimental research project on pallasites. BGI offers excellent conditions for this research work, says the up-and-coming Bayreuth researcher.

University of Bayreuth

Header Image Texture of a pallasite: The brown and golden-brown areas contain olivines which are embedded in iron-nickel metal. Width: 3.5 cm. Image Credit : Audrey Bouvier

See the rest here:

Researchers Explain the Origins of Stony-Iron Meteorites - HeritageDaily

New 3D model reveals Venus’ volcanoes are actually still active – TNW

Across the lansdcape, steam vents hiss gaseous breath from deep inside the planet, creating an environment that feels like it hangs in the balance between our world and another. Stefanie Payne, A Year in the National Parks: The Greatest American Road Trip

The team designed models of geological activity beneath the surface of Venus. These 3D models of showed the formation of coronae formation identified features that could only be produced by recent volcanic activity on the surface of Venus. This finding provides the first evidence that the surface of Venus is still active, betraying active geology beneath the crust.

I focus on the lithosphere and surface geology, which is relatively accessible to planetary missions data. I like to call this kind of work comparative planetology. Venus is of special interest because of its gross similarity to the Earth. Yet the geology we observe is very different from that of the Earth. It has volcanoes and faults, yes, but they are organized very differently from the Earth. It does not have global tectonics like we do (at least at present day), Montsi tells The Cosmic Companion.

Without plate tectonics, movement of hot material through the planetary surface is the dominant force driving geological change on Venus today.

In the video above, you can take look at the planned EnVision mission to Venus, scheduled for launch in 2032. (Video credit: Thomas Widemann)

The surface of Venus was likely reworked on a large scale by volcanoes between 500 and 300 million years ago. Eruptions there have some similarities, as well as some differences to geological activity here on Earth.

Volcanoes on Venus actually look a lot like those on Earth: they have similar slope, activity on the summit etc. However, there are many regions of Venus that are covered with lava flows without necessarily a clear source. We see that in a few places on Earth, in regions called flood basalt provinces or traps. In our study we focused on very unusual structures called coronae, which do not have a good equivalent in terrestrial geology. They have a ring of faults and lava flow, and their interior can be quite complex, maybe have volcanic edifices, but these are not very well documented yet, Montsi describes.

This finding could assist teams heading future missions to Venus, including Europes EnVision mission, scheduled for launch in 2032.

This article was originally published on The Cosmic Companion by James Maynard, founder and publisher of The Cosmic Companion. He is a New England native turned desert rat in Tucson, where he lives with his lovely wife, Nicole, and Max the Cat. You can read this original piece here.

Astronomy News with The Cosmic Companion is also available as a weekly podcast, carried on all major podcast providers. Tune in every Tuesday for updates on the latest astronomy news, and interviews with astronomers and other researchers working to uncover the nature of the Universe.

See the rest here:

New 3D model reveals Venus' volcanoes are actually still active - TNW

Global Genetic Engineering Vector Market Analysis Recent Trends And Regional Growth Forecast By Types And Applications 2020 – Bulletin Line

Global Genetic Engineering Vector Market Research Report Covers the existing situation and the development predictions of the industry for 2020. This Report has been prepared primarily based mostly on particular market assessment with inputs from industry experts. This estimated report consists of all have observed element about marketplace evaluation, increase Demand and forecast analysis in all over the world. This record gives a few edged examine and solution within the complicated international of polymer-based totally thermal interface materials market.

Key Players:- Company A And More

Genetic Engineering Vector market report describes the growth of the industry by upstream & downstream, the industry overall and development, key companies, as well as type segment & application and so on, and makes a scientific prediction for the development industry forecasts based on an analysis.

Get Sample Copy Of Report From Here and Get Instant 10% Discount : https://www.eonmarketresearch.com/sample/72606

Genetic Engineering Vector Market research report quantifies opportunities and Challenges to prioritize with the revenue. Then report explains each component thoroughly like business Strategies, Industry trends, Regional Development, Performance matrix. This vital data about Genetic Engineering Vector industry will help to improve market growth in terms of manufacturing capacity, Sales during the Forecast period of 2020.

Genetic Engineering Vector Market regional analysis covers the following regions: North America, Europe, Asia-Pacific, South America, Middle East & Africa.

The scope of the Report: This report focuses on the Genetic Engineering Vector in the global market, especially in Europe, North America, and Asia-Pacific, Middle East, and Africa, South America. This report describes the market based on regions, type, manufacturers, and application.

Buy This Premium Report: https://www.eonmarketresearch.com/buy/72606

Market Segment On The Basis Of Product Type Includes:-

General Type

Applications Mentioned In This Report:-

In Vitro StudiesClinical

The report then estimates 2020 market development trends of Genetic Engineering Vector market. Outline of upstream raw materials, downstream trade and prevailing market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Genetic Engineering Vector market before evaluating its feasibility.

This report presents an extensive analysis of the current Genetic Engineering Vector trends and emerging estimations & dynamics of the global Genetic Engineering Vector industry. Likewise, explains the comprehensive analysis of factors that drive and restrict the growth of the Genetic Engineering Vector market. Further covers a detailed analysis of the Genetic Engineering Vector industry based on type and application help in understanding the Genetic Engineering Vector trending products across geographies. Then highlights the potency of buyers and suppliers to understand the Genetic Engineering Vector market potency. Finally, an extensive analysis of the Genetic Engineering Vector market is conducted by key product positioning and monitoring of top players within the Genetic Engineering Vector market framework.

Place An Inquiry Before Investment @ https://www.eonmarketresearch.com/enquiry/72606

Table of Contents

1. Industry Overview of Genetic Engineering Vector2. Global Genetic Engineering Vector Competition Analysis by Players3. Company Profiles4. Global Genetic Engineering Vector Market Size by Type and Application (2020-2025)5. United States Genetic Engineering Vector Development Status and Outlook6. EU Genetic Engineering VectorDevelopment Status and Outlook7. Japan Genetic Engineering Vector Development Status and Outlook8. China Genetic Engineering Vector Development Status and Outlook9. India Genetic Engineering Vector Development Status and Outlook10. Southeast Asia Genetic Engineering Vector Development Status and Outlook11. Market Forecast by Regions, Type, and Application (2020-2025)12. Genetic Engineering Vector Market Dynamics13. Market Effect Factors Analysis14. Research Finding/Conclusion15. Appendix

**Thanks for reading this article; you can also get individual chapter wise section or region wise report version like United States, Europe, Middle East, and Africa or Asia-Pacific.**

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: [emailprotected]

Read the original:

Global Genetic Engineering Vector Market Analysis Recent Trends And Regional Growth Forecast By Types And Applications 2020 - Bulletin Line

Allow field trials of Bt brinjal to ensure safety of crops, agri-tech body writes to govt – ThePrint

Text Size:A- A+

New Delhi: The Alliance for Agri Innovation (AAI), a leading agri-tech industry body, has written to the central government and various states to allow field trials of Bt brinjal, a genetically-modified (GM) crop that was banned in 2010 following concerns raised about public health and biodiversity.

In a statement released Friday, the AAI said field trial was the only way to ensure safety of crops. blocking such trials amounts to blocking national development, it said.

AAIs letter has been sent to the agriculture ministry and chief ministers of Madhya Pradesh, Karnataka, Bihar, Chhattisgarh, Jharkhand, Tamil Nadu, Odisha and West Bengal.

The AAI statement also mentions how a 2019 peer-reviewed study had found that net returns to farmers from Bt brinjal crop averaged $2151/ha (Rs 1.61 lakh/ha) compared to $357/ha (Rs 26,768/ha) from non-Bt brinjal crop.

In India, Bt brinjal was cleared for commercial cultivation by the Genetic Engineering Appraisal Committee (GEAC) in 2009 but it was placed under an indefinite moratorium the following year by then minister of state for environment, Jairam Ramesh.

Several farmers from various states, including Maharashtra and Haryana, were found to be openly flouting the GM crop ban last year and sow Bt brinjal.

The crop has been commercially grown in Bangladesh since 2014 the first South Asian country to do so.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrints future.

SUBSCRIBE NOW

Also read: Why farmers are still having to protest for their right to sow GM seeds, even in a pandemic

Brinjal is an extremely pest-prone crop, and highly susceptible to the fruit and shoot borer (FSB) pest.

To reduce loss of yield, farmers often end up spraying this crop multiple times. A report from Bangladesh had earlier noted that protein in Bt brinjaldisrupts the digestive systems of certain pests, causing them to die within three days of ingestion.

It had also stated that advantages of using Bt brinjal over non-Bt brinjal were lower pest infection, higher yields, 56 per cent reduction in environmental toxicity and fewer complaints about symptoms consistent with pesticide exposure.

Ram Kaundinya, director general of AAI, said in the statement, The deadly FSB is a menace for farmers and its caterpillar also finds its way into our homes through infected brinjals. By controlling this with Bt technology, we can save farmers income, reduce pesticide load on the environment and provide pesticide- and insect-free brinjals to consumers.

AAI head Paresh Verma added, Development of indigenous technology is in line with the Atmanirbhar Bharat mission launched by Prime Minister Narendra Modi. Delays due to a paralysis in the decision-making process by the central and state governments have essentially stalled the progress in research to develop new technologies.

The AAI statement also noted how several studies and analyses into GM cultivation over the past 23 years have found no evidence of adverse health effects on humans or animals.

Also read: Now, Bangladesh set to steal march over India with GM rice that fights malnutrition

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the medias economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the countrys most robust editing and fact-checking team, finest news photographers and video professionals. We are building Indias most ambitious and energetic news platform. And we arent even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrints future. It will take just a few seconds of your time.

Support Our Journalism

See the original post:

Allow field trials of Bt brinjal to ensure safety of crops, agri-tech body writes to govt - ThePrint

What to Watch When Twist Bioscience Reports Fiscal Q3 Results – Motley Fool

Uncertainty is one of the central themes of investing in 2020, but investors can be certain of one thing: Valuing shares of Twist Bioscience (NASDAQ:TWST) at more than 30 times sales is a little bit ridiculous.

The company's technology platform is intriguing, but it hasn't shown signs of becoming a commercial success from a business standpoint. In fact, Twist Bioscience has reported growing losses as it has scaled its business and relied on equity financing to fund operations. That hasn't stopped the small-cap stock from soaring by more than 200% since the beginning of 2020.

On the one hand, Twist Bioscience is uniquely positioned to help customers respond to the coronavirus pandemic. It has also signed a flurry of drug discovery deals this year. On the other hand, the financial impacts of those catalysts are a bit fuzzy. Here's what metrics investors will be watching when the company reports fiscal third-quarter 2020 operating results.

Image source: Getty Images.

Twist Bioscience is developing a DNA synthesis technology platform that can be used in drug discovery, genetic engineering experiments, and diagnostic panels. It's not necessarily the technological endgame, but it's the best we have right now. Heck, the company supplies many of its competitors with synthetic DNA.

And its technology platform looks to be playing an important role in the global response to the coronavirus pandemic. Twist Bioscience has created synthetic controls of the SARS-CoV-2 virus that can be used in diagnostic tests to detect whether a person is currently infected, launched SARS-CoV-2 antibody panels for research activities, and inked drug discovery deals with biopharmaceutical companies developing therapeutic antibodies to treat COVID-19.

Additionally, the company doesn't appear to have slowed future-oriented investments in its technology platform and businesses. Twist Bioscience has signed non-COVID-19 drug discovery deals with Takeda Pharmaceuticals, Seismic Bio, and Invetx (an animal health start-up) since the end of the fiscal second quarter of 2020.

The biggest question facing investors is pretty simple: Will announcements translate into tangible progress?

Investors are assuming Twist Bioscience will report a noticeable bump in quarterly revenue from coronavirus-oriented research tools, although financial details weren't disclosed for any of the drug discovery deals. The latter appear to be dependent on technology access fees and milestone or royalty payments, which wouldn't necessarily have a significant near-term impact.

Here's the problem: Even an incredible quarter probably isn't enough to make sense of the stock's current valuation. Investors shouldn't be paying 30 times sales for a money-losing business that has grown operating losses faster than gross profit and is entirely reliant on stock offerings to keep the lights on.

In other words, even a relatively strong quarter could cause the stock to drop. There's simply too much success baked into the company's market valuation right now. It's difficult to see how Twist Bioscience's $3 billion valuation is sustainable with publicly available information. Then again, it's 2020. Many stock valuations don't make much sense right now.

A great business is always a great investment in the long run, but a great investment is not always a great business. Thus far in 2020, Twist Bioscience has been a great investment, but the stock's ascension is detached from business fundamentals. That's likely to be true even with an amazing increase in revenue from the coronavirus pandemic, assuming that's what the results show. Investors might want to take that into account, as starting or adding to a position at current prices might sap long-term returns. Unless the company announces a major event that's not currently on investors' radar, it's simply difficult to see shares holding onto recent gains.

Here is the original post:

What to Watch When Twist Bioscience Reports Fiscal Q3 Results - Motley Fool

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020 – Stockhouse

Key Highlights:

WILLIAMSVILLE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (22nd Century” or the Company”), a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding, today reported results for the second quarter ended June 30, 2020.

Despite the unprecedented challenges brought on by COVID-19, I am pleased to report net sales revenue of $6.4 million for the second quarter of 2020, up 11% from the prior year, continued gross profit margin expansion, and improved operating loss. These results demonstrate our ability to execute on our initiatives to improve our margins and cost structure. Our financial position remains strong and we will continue to operate with strict cost controls, allocate our resources efficiently, and deploy capital where we believe it will give us the greatest return on our investments,” said James A. Mish, Chief Executive Officer of 22nd Century Group.

With the comment period now closed on our Modified Risk Tobacco Product Application, the team is laser focused on setting the stage for a successful VLN® launch upon the authorization of our MRTP Application by the FDA. I am exceedingly proud of the dedication and tremendous progress the team has made so far this year and believe we are well positioned to capitalize on the many opportunities ahead,” Mish added.

Business Highlights and Notable Events:

COVID-19 Update

2020 Second Quarter and Year-to-Date Financial Results

Balance Sheet and Liquidity

Second Quarter Earnings Conference Call 22nd Century will host an audio-only webcast today at 8:00 a.m. ET to discuss the Company’s second quarter 2020 financial results.

The live audio webcast will be accessible in the Events section on the Company's Investor Relations website at http://www.xxiicentury.com/investors/events. An archived replay of the webcast will also be available shortly after the live event has concluded.

About 22nd Century Group, Inc. 22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking by bringing its proprietary reduced nicotine content tobacco cigarettes containing 95% less nicotine than conventional cigarettes to adult smokers in the U.S. and international markets. The Company’s primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with valuable cannabinoid profiles and agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.

Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn.

Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements concerning our business, operations and financial performance and condition as well as our plans, objectives and expectations for our business operations and financial performance and condition that are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. You can identify these statements by words such as aim,” anticipate,” assume,” believe,” could,” due,” estimate,” expect,” goal,” intend,” may,” objective,” plan,” potential,” positioned,” predict,” should,” target,” will,” would” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management's beliefs and assumptions. These statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All forward-looking statements are subject to risks and uncertainties and others that could cause actual results to differ materially from those contained in our forward-looking statements. Please refer to the Risk Factors” in our Annual Report on Form 10-K filed on March 11, 2020 and in our subsequently filed Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law

Adjusted EBITDA, which the Company defines as earnings before interest, taxes, depreciation and amortization, as adjusted by the Company for certain non-cash and non-operating expenses, as well as certain one-time expenses, is a financial measure not prepared in accordance with generally accepted accounting principles (GAAP”). In order to calculate Adjusted EBITDA, the Company adjusts the net (loss) income for certain non-cash and non-operating income and expense items listed in the table above in order to measure the Company’s operating performance. The Company believes that Adjusted EBITDA is an important measure that supplements discussions and analysis of its operations and enhances an understanding of its operating performance. While management considers Adjusted EBITDA to be important, it should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating loss, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company’s measurement of Adjusted EBITDA may not be comparable to those of other companies.

Below is a table containing information relating to the Company’s Adjusted EBTIDA for the three and six months ended June 30, 2020 and 2019, including a reconciliation of net (loss) income to Adjusted EBTIDA for such periods.

Contacts: Mei Kuo 22nd Century Group (716) 300-1221 mkuo@xxiicentury.com

John Mills ICR (646) 277-1254 john.mills@icrinc.com

Deirdre Thomson ICR (646) 277-1283 deirdre.thomson@icrinc.com

See the original post:

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020 - Stockhouse

Viewpoint: Battling deadly disease with gene drives is worth the limited risk – Genetic Literacy Project

The fate of society rests in part on how humans navigate their complicated relationship with insects trying to save good insects and control bad ones. Some insects, like mosquitoes, bite people and make them sick remember Zika? Now the U.S. mosquito season is already in full swing, withover 10 cases of Dengue feverreported in the Florida Keys this year. Some insects, likebees, are pollinatorsthat help produce our food. Others, likelocusts, currently threaten cropsin East AfricaandAsia, preferring to eat our food instead.

Insects have proven themselves extremely capable at evolving strategies to get around control methods, such as chemical insecticides and habitat modification, and current pest control technologies are simply not keeping up.

We arebothinsect scientists. Our research has includedengineering a fungus to control malaria mosquitoes,uncovering the reproductive biology of honey bee workersand understanding thehealth impacts of invasive ticks. Weve come to appreciate the potential of emerging technologies like gene drive. This technology can guarantee that a trait will be inherited by the next generation. Such traits include making mosquitoesimmune to the malaria parasiteso they cannot spread the disease to humans.

Recently we contributed to astatement that advocates for continuing gene drive research. In light ofcalls for a moratorium, this statement recognizes that a ban on gene drive research would hamper a better understanding, and thus mitigation, of risks associated with this technology.

Moratoriums on gene drive technology have been called for and rejectedat the last twoUnited Nations Conventions on Biological Diversity. But there isa new push for a moratorium.

Gene drive is a technology that could allow society to control insects in a more targeted manner.

The general underlying principle of all gene drives is an organism that will produce offspring similar to themselves.

Some characteristics are randomly passed on from parents to the next generation. However, gene drive forces a different type of inheritance that ensures a specific characteristic is always present in the next generation. Scientists engineer gene drive using various molecular tools.

Gene drive is not just a human invention; some occur naturally in insects. For example, instalk-eyed flies, a gene on a sex-related chromosome causes any male fly to die without a certain gene cargo, including a gene that results in longer eyestalks. This type of genetic phenomenon has been well studied by scientists.

To date, gene drive has been discussed in the media primarilyin order to eradicate malaria. This may give you the impression that gene drive can be used onlyto drive mosquitoes to extinction. However, gene drive technologies are highly versatile and can be designed to bring about different outcomes. They can also be applied in most insect species that scientists can study in the laboratory.

Insects reproduce quickly and produce lots of offspring, which makes them obvious candidates for a technology that relies on inheritance like gene drive. This is why insects are at the leading edge of gene drive research. Gene drive is a new technology that could provide a solution to a variety of insect issues society faces today.

For instance, a gene drive has beendeveloped to stop a major crop pest, the spotted-wing Drosophila. Insecticide sensitivity could be spread through populations of this pest species to stoptens of millions of dollars in crop damage every yearin the United States.

Gene drive could also be a more targeted approach to stopping invasive insects, such as the infamousfire ant, from destroying native ecosystems. In the United States, millions of dollars have been spent onremoving fire ants using techniques including chemical insecticides, but if these persistent ants are not completely eradicated, they invade again.

Aside from how good insects are at circumventing our strategies to control them, another major struggle for controlling insects is finding them. Insects have evolved to quickly find the opposite sex to mate, and gene drives, which are passed on by mating, can take advantage of this fact of insect life. This also means this technology targets only the intended species, which is not the case for chemical insecticides currently in use.

Insect scientists, inspired by natural examples of gene drive, have wanted to design gene drive in insects for decades. Only recently have new molecular tools, such as the gene editing toolCRISPR-Cas, made the gene drive dream a reality. For now, gene drive insectslive in laboratories and none has been released into the wild. Still, a lot can be learned about how gene drive works while it is safely contained in a laboratory.

Using gene drive is not a universally popular idea. Criticisms tend to fall into three categories: ethical concerns, mistrust of technology and unintended ecological consequences.

Ethical concerns about gene drive are often motivated by larger issues, such as how to stop gene drive from being used in biological weapons by engineering insects that are more dangerous. Then there is the question of who should decide which gene drive projects move forward and what types of insects with gene drive can be released into the environment. These questions cant be answered by scientists alone.

Societal mistrust of technologyis a hurdle that some powerful, innovative technologies must overcome for public acceptance. The issue of technological mistrust often stems from disagreements about who should be developing technology to control insects and for what purposes.

The third common argument against gene drive technologies is that they might cause unintended consequences in the ecosystem because gene drive is designed by humans and unnatural. What will happen to the natural ecosystem if a population, even of mosquitoes that make people sick, is driven to extinction? Will this cause threats to natural biodiversity and the security of food? These questions are ultimately asking the consequences of intervening in the natural order of the world. But who defines what is the natural state of an ecosystem?Ecosystems are already constantly in flux.

When a gene drive is developed, it is tailored to the needs of a particular situation. This means theanticipated risksposed by each gene drive are project-specific and should be considered and regulated on a case-by-case basis. A responsible way to protect society from these risks is to advocate for continued research that enables scientists to describe and find solutions to them. Beyond the science, regulatory and accountability systems are needed so that regulations are adhered to and public safety is protected.

Researchers are also still exploring the science underlying the gene drive. Can gene drive be designed to be reversible or more efficient? Can the effect of a gene drive on an ecosystem be predicted? Such important unanswered questions are why even the most ardent supporters of this technology say more research is needed. Society needs new tools to control insect pests and protect ecosystems, and gene drive promises to augment our toolbox.

Isobel Ronai is an Endeavour Postdoctoral Research Fellow at Columbia University. Follow her on Twitter @IsobelRonai

Brian Lovett is a postdoctoral researcher at the Division of Plant and Soil Sciences at West Virginia University working on fungal biology and biotechnology. Follow him on Twitter @lovettbr

This article was originally published at the Conversation and has been republished here with permission. Follow the Conversation on Twitter @ConversationUS

Read the original here:

Viewpoint: Battling deadly disease with gene drives is worth the limited risk - Genetic Literacy Project

NASAs Curiosity Rover Reaches an Impressive Milestone During its Mars Mission – Webby Feed

Home News NASAs Curiosity Rover Reaches an Impressive Milestone During its Mars Mission

The Curiosity rover was sent to Mars by NASA in 2012 in order to study the planets Gale Crater. The bigger goal was to find out if the crater could have supported life as it exists on Earth. Very few people suspected that Curiosity could go so far as it did. Life wasnt found on Mars until now, but Curiosity reached an unprecedented milestone.

Its time to say Happy Birthday! to the Curiosity rover that had been roaming the Martian surface for eight wonderful years.

NASAs Curiosity rover celebrated its 8th anniversary yesterday, on August 5. The rover didnt find any little green men living on the Red Planet, but it still had enormous contributions for making scientists understand the planet a lot better.

Judging by the data gathered by the Curiosity rover, scientists were able to conclude that the Gale crater from Mars hosted a potentially habitable lake-and-stream system. The rover also found some complex organic chemicals on Mars.

Space agencies are continuing to explore the Red Planet in order to find out all the possible dangers that astronauts could be facing there. NASA plans to send humans to the Moon after more than half a century, along with the Artemis program. If everything goes according to the plan, the next destination is Mars. Scientists hope to begin the terraforming of Mars in the future, but we are naive to think that well be able to move our luggage on the Red Planet in less than a hundred years. But for a short visit to Mars, that wouldnt be a problem with the current technology.

If the distance between Earth and the Moon is only 384,000 kilometers, well have to travel much more if we want to arrive to our neighboring planet. The shortest distance between our planet and Mars is 54.6 million kilometers.

Related

More here:

NASAs Curiosity Rover Reaches an Impressive Milestone During its Mars Mission - Webby Feed

Regulatory Focus, July issue: Cell and gene therapy – Regulatory Focus

Feature articles during July focused on global regulatory strategy for cell and gene therapy, with articles on US and EU regulations and guidances and the development and manufacture of the therapies. Also included were articles on recasting the corrective and preventive action (CAPA) process as a continuous improvement process, a military-civilian perspective on real-world evidence (RWE) to support regulatory decision making, and regulatory reporting in multinational trials during COVID-19.Advanced therapy medicinal products (ATMPs), including cell therapies, gene therapies, and tissue-engineered products, are highly complex treatments that differ from traditional medicines, both in how they are made and administered and in the benefits they may provide. Regulations for these products were established relatively recently and are still evolving in many jurisdictions globally. The novelty of these products, the inherent complexities of cell and gene therapy products, and the lack of experience with such products pose many challenges for developers.In part one of this two-part series, this months expert authors address these challenges and offer hands-on, practical advice and guidance on regulation and production of ATMPs. If there is one clear, take-home message to developers, it is that early and frequent collaboration with regulatory agencies, during both the approval and development phases, is paramount. It saves time and money, and it reduces the risk of a negative impact on the trajectory of a clinical trial. Part 2 of the series will cover upstream manufacturing and process controls for biologics, the ATMP regulatory landscape in China, EU GMP requirements for autologous cell therapies and parenteral biologics, and regulatory challenges and opportunities in the US.Regulations and guidancesThe regenerative medicine advanced therapy (RMAT) field has the potential to provide profound benefits to patients with serious diseases and disorders, and the RMAT designation is helping drive these transformative technologies to market. In Update on RMAT designations, William K. Sietsema and Janet Lynch Lambert discuss the scope and purpose of the special designation for RMATs created by the passage of the 21st Century Cures Act and provide a tally of products that have received the special designation to date. However, while the promise of regenerative medicines to cure disease is propelling the field at a rapid pace, developing these therapies requires a rigorous, carefully planned approach to ensure a seamless progression to regulatory approval and commercial success.Siegfried Schmitt expands on that point about carefully navigating the complex and nuanced regulatory environment in two articles on US and EU regulations for RMATs and ATMPs, respectively. In US regulations for regenerative medicine advanced therapies, he provides a user-friendly, quick-access list of RMAT-related regulations and guidances. The article includes a useful introduction to the application process and descriptions of the features and criteria for various expedited program options, including breakthrough therapy, fast track, advanced approval, and priority review.In Regulation of advanced therapy medicinal products in the EU, Schmitt explains some of the terminology relating to ATMPs before documenting the key EU regulations and guidances for each therapy type. He concludes with discussions on marketing authorization, accelerated regulatory pathways, and market access. Again, he urges companies and developers to engage with the regulatory agencies early and often throughout the approval process and to seek external regulatory support, especially if the developer has limited in-house regulatory resources.Development pathways and manufacturingTwo articles shift the focus from the regulatory landscape to development and manufacturing pathways. The drug manufacturing facility environment presents one of the major sources of potential contaminants in the final biologic drug product, so it is critical to design facilities with cleanroom environmental controls and monitoring that adhere to the highest standards of current good manufacturing practice (cGMP) quality guidelines, write Mo Heidaran and colleagues. In Designing a biologics manufacturing facility: Early planning for success, the authors lay out the planning steps for compliance with cGMP to readiness for chemistry, manufacturing, and controls (CMC). The authors warn that the pressure to reduce time to market put considerable stress on all aspects of commercial operations and commercial-scale manufacturing development, so yet again, early tactical and strategic planning essential.In Advanced therapies: Trip hazards along the development pathway, Kirsten Messmer and Richard Dennett focus on the challenges and complexities of ferrying advanced therapies along the developmental pathway, which they call the trip. They examine the importance of some of the fundamental building blocks for the development program and highlight some commonly encountered challenges, or trip hazards, for cell and gene therapies. The suggest developers establish sound technical and regulatory strategies to better anticipate and avoid the trip hazards, which could prove costly, both in time and money, and have a negative impact the overall clinical study program.CAPA, RWE, and COVID-19Todays CAPA process has become highly focused on compliance, which has manufacturers struggling to determine which issues require a structured CAPA process and which can be resolved in alternative ways, writes Kathryn Merrill in Recasting CAPA as a continuous improvement process. Merrill summarizes a white paper developed by the Medical Device Innovation Consortium, in which the CAPA process is recast as a continuous improvement process for driving higher product quality and improved patient safety. It is intended to enable organizations make a greater number of improvements more quickly, and over time, which will have a favorable impact on product quality in the field.During the Afghanistan and Iraq wars, the US Military Health System used an approach known as focused empiricism to develop new approaches for casualty care. In doing so, it implemented real-world data (RWD) and RWE into a system of performance improvement and product development to achieve historic rates of survival, write Todd E. Rasmussen, a colonel in the US Air force, and Brian J. Young. In A military-civilian perspective on real-world evidence to support regulatory decision making, the authors summarize the framework promoting the collection and analysis of RWD in the healthcare system and describe a new era of collaboration between the US Department of Defense and the FDA, within the context of a new Public Law 115-92, to coordinate on the delivery of military-relevant medical products. The article reviews the FDA evidentiary standards for medical product approval and gives examples of how RWE can help meet those standards.COVID-19 continues to disrupt and redefine the regulatory process and activity. In Managing uncertainty: Regulatory reporting in multinational trials during COVID-19, Ioana Ionita discusses regulatory reporting challenges for multinational clinical trials during the pandemic, as well as the challenge of assessing what is reportable and how to submit COVID-19 risk mitigation measures. She offers real-world experience on how she and her colleagues stopped and restarted recruitment in ongoing multinational clinical trials, and how those actions were reported globally. Ionita concludes that close collaboration between sponsors, CROs, local affiliates, investigational sites, and health authorities is important in choosing strategies under challenging circumstances and when no precedent applies.Whats coming in August?Articles during August will focus on global clinical trials and clinical trial applications. Despite ICH efforts to produce guidelines for the development of drugs and biologics and to standardize the format of marketing applications, there remain considerable differences among countries in the format of clinical trial applications and health authority review processes. This collection of articles will address these divergent formats and processes and provide options for navigating the regulatory aspects of clinical trials. Look for these topics and more throughout August at http://www.raps.org.October call for articlesFor October, Regulatory Focus will look at the regulatory toolboxthe tools regulatory professionals need and where to find them, with an emphasis on websites, guidances, meeting minutes and FDA correspondence, including warning letters, enforcement actions, 483s, and notices. Articles will discuss how to interpret the meaning behind regulatory agency actions and available options for documentation. The submission deadline for articles is 1 September 2020. To contribute to the October issue or suggest a topic, contact Rene Matthews at rmatthews@raps.org.Citation Matthews R. Regulatory Focus, July issue: Cell and gene therapy. Regulatory Focus. July 2020. Regulatory Affairs Professionals Society.

More here:

Regulatory Focus, July issue: Cell and gene therapy - Regulatory Focus

G-CON PODs Selected for Expression Therapeutics’ Gene Therapy Manufacturing Facility – PR Web

Photo courtesy of Expression Therapeutics

COLLEGE STATION, Texas (PRWEB) August 05, 2020

G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, announced today that it has been selected by Expression Therapeutics to support its cleanroom build-out at its new clinical manufacturing facility in Cincinnati, Ohio. The PODs will provide the cleanroom infrastructure for the production of Expression Therapeutics cell and gene therapies.

For this project, time was a critical factor for Expression Therapeutics. Offsite manufacturing of the cleanroom infrastructure allowed for concurrent preparation of their new host facility, significantly reducing the projects overall timeline. Future expandability was also key, as their POD system is being designed to accommodate Expression Therapeutics cleanroom needs for its next phase. Removable panels incorporated into the POD walls will easily allow integration of additional POD clean space. Since PODs are autonomous and completely assembled offsite, this expansion will result in minimal downtime and disruption to the functioning first phase POD cleanrooms.

Its great to work in an industry where innovation moves so fast and helps people live better lives, said Tim Rasmussen, Sales Engineer at G-CON Manufacturing. Companies like Expression Therapeutics need infrastructure to develop breakthrough therapies, and they need them fast. We are proud to play a part in making patients lives better by delivering state of the art cleanroom solutions more quickly than any other solution on the market.

We decided to utilize advanced pre-built modular cleanrooms from G-CON to accelerate our buildout and commence vector manufacturing this year. With vector GMP manufacturing backlogs today typically exceeding 18 months, we wanted to bring on additional capacity as soon as possible to serve clients said Bill Swaney, Vice President of Manufacturing for Expression Therapeutics.

About G-CON ManufacturingG-CON Manufacturing designs, builds and installs prefabricated G-CON POD cleanrooms. G-CONs POD portfolio provides cleanrooms in a number of dimensions for a variety of uses, from laboratory environments to personalized medicine and production process platforms. G-CON POD cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end. For more information, please visit G-CONs website at http://www.gconbio.com.

G-CON Manufacturing... BUILDING FOR LIFE

About Expression TherapeuticsExpression Therapeutics is a biotechnology company based in Atlanta and Cincinnati. The current therapeutic pipeline includes advanced gene therapies for hemophilia, neuroblastoma, T-cell leukemia/lymphoma, acute myeloid leukemia (AML), and primary immunodeficiencies such as hemophagocytic lymphohistiocytosis (HLH).

Share article on social media or email:

See the rest here:

G-CON PODs Selected for Expression Therapeutics' Gene Therapy Manufacturing Facility - PR Web

CRISPR co-discoverer on the gene editor’s pandemic push – Axios

The coronavirus pandemic is accelerating the development of CRISPR-based tests for detecting disease and highlighting how gene-editing tools might one day fight pandemics, one of its discoverers, Jennifer Doudna, tells Axios.

Why it matters: Testing shortages and backlogs underscore a need for improved mass testing for COVID-19. Diagnostic tests based on CRISPR which Doudna and colleagues identified in 2012, ushering in the "CRISPR revolution" in genome editing are being developed for dengue, Zika and other diseases, but a global pandemic is a proving ground for these tools that hold promise for speed and lower costs.

Driving the news: Last week, the NIH awarded $250 million for the development of COVID-19 diagnostic tests to a handful of companies, including Mammoth Biosciences, which is working on a CRISPR-based test that CEO Trevor Martin says will deliver 200 tests per hour per machine.

The challenge now is "getting it into a format where it can be used easily either in a laboratory or at the point-of-care," like the doctor's office or home, she says.

How it works: Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR, are sequences of genetic code that bacteria naturally use to find and destroy viruses.

That editing ability is viewed as having vast potential for treating disease, a nascent use of CRISPR.

But there's a persistent problem: Getting the sizable CRISPR system through the membranes and to the DNA of the cells that need editing.

And, there are other concerns about off-target editing with currently available enzymes and unknown long-term effects of gene editing directly in the body.

The intrigue: CRISPR could one day be wielded in future pandemics.

Yes, but: That would require sophisticated understanding of how a virus changes and the immune system's complex response to it.

The big picture: Such "genetic vaccination" is a long way off, but it could eliminate having to wait until a virus shows up, make a vaccine to that virus and then vaccinate people, she says.

See the original post:

CRISPR co-discoverer on the gene editor's pandemic push - Axios